Dr. Ruben Mesa is Director of UT Health San Antonio Cancer Center and is Mays Family Foundation Distinguished University Presidential Chair Professor of Medicine. He is committed to improving therapeutic options and quality of life for patients with chronic myeloid disorders such as myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia and myelofibrosis. Previously, Dr. Mesa served as Chair of the Division of Hematology & Medical Oncology at Mayo Clinic in Arizona and Deputy Director of the Mayo Clinic Cancer Center.
Dr. Mesa has been principal investigator or co-principal investigator in more than 50 clinical trials for patients with myeloproliferative neoplasms or other myeloid disorders. He is currently the Panel Chair for the National Cancer Center Network (NCCN) MPN Treatment Guideline Panel. Additionally, Dr. Mesa is co-principal investigator of the Clinical Trial Group of the Myeloproliferative Disorders Research Consortium (MPD-RC). He currently serves as the Chair of the Arizona Cancer Coalition, which oversees the Arizona Cancer Control Plan and works with the Arizona Department of Health Services in advocating for Cancer in the State of Arizona. Dr. Mesa is a clinical advisor to The Leukemia & Lymphoma Society and is chair of the Standing Science and Education Committee for the International Society of Hematology.
Dr. Mesa has over 800 lifetime medical publications, and serves as the Editor-in-Chief of Current Hematology Malignancy Reports. He serves as an editorial board member for several journals including Blood, Journal of Clinical Oncology, Advances in Hematology, American Journal of Hematology/Oncology, European Medical Journal – Haematology, Journal of Blood Disorders & Transfusion, Revista De Hematologia and Revista Hematologica Mexicana. Dr. Mesa is a frequently invited speaker on the MPNs with over 600 such lectures, and visiting professorships, nationally and internationally. He discloses that he has received research support from Incyte, Gilead, CTI, Promedior, and Celgene. Dr. Mesa has been a consultant to Novartis, Ariad and Galena.